Loading
New York haematologist who led MANIFEST-2, the trial testing whether adding the BET inhibitor pelabresib to ruxolitinib helps people with myelofibrosis more than ruxolitinib alone.
Raajit Rampal directs the myeloproliferative neoplasms programme at Memorial Sloan Kettering Cancer Center. He was the global lead investigator and first author of the primary report of MANIFEST-2, the phase 3 trial of pelabresib plus ruxolitinib against placebo plus ruxolitinib in JAK inhibitor-naive myelofibrosis, which met its spleen-volume primary endpoint. His research covers the genetics of progression from chronic myeloproliferative neoplasms to acute leukaemia.
| Title | Journal | Year |
|---|---|---|
| Single-cell mutation analysis of clonal evolution in myeloid malignancies Europe PMC author record matched by affiliation (Memorial Sloan Kettering Cancer Center); 456 citations on Europe PMC. | Nature | 2020 |
| Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis Europe PMC author record matched by affiliation (Memorial Sloan Kettering Cancer Center); 349 citations on Europe PMC. | Blood | 2014 |
| JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response Europe PMC author record matched by affiliation (Memorial Sloan Kettering Cancer Center); 279 citations on Europe PMC. | Cancer Discovery | 2015 |
One of the most cited papers Europe PMC returns for Raajit K. Rampal at Memorial Sloan Kettering Cancer Center, so it is a natural starting point for reading their work. The record was linked automatically from the author list and affiliation; read the abstract above and the paper itself before relying on any figure.
One of the most cited papers Europe PMC returns for Raajit K. Rampal at Memorial Sloan Kettering Cancer Center, so it is a natural starting point for reading their work. The record was linked automatically from the author list and affiliation; read the abstract above and the paper itself before relying on any figure.
One of the most cited papers Europe PMC returns for Raajit K. Rampal at Memorial Sloan Kettering Cancer Center, so it is a natural starting point for reading their work. The record was linked automatically from the author list and affiliation; read the abstract above and the paper itself before relying on any figure.
Shares Primary myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tags mpn, trialist.
Shares Primary myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag mpn.
Shares Primary myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag mpn.
Shares Memorial Sloan Kettering Cancer Center and the tag trialist.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag mpn.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag mpn.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag mpn.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag mpn.